Funded in part by Novartis, Germany
Serum 25-hydroxyvitamin D levels in patients with skin diseases including psoriasis, infections, and atopic dermatitis
Amon U, Baier L, Yaguboglu R, Ennis M, Holick MF, Amon J
Dermato-endocrinology · 27 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cross-sectional study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Novartis, Germany
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2018-01-01 · Dermatoendocrinol · vol. 10 · issue 1 · p. e1442159
- Publisher
- Taylor & Francis
- Cited
- 44 citations · more than 90% of similar papers · 2.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 85 works
- Access
- Open access (free to publish) · CC-BY-NC-ND
- Research areas
- Vitamin D Research Studies · Dermatology and Skin Diseases · Psoriasis: Treatment and Pathogenesis
- Keywords
- Atopic dermatitis, Psoriasis, Dermatology, Medicine, Vitamin D and neurology, Immunology, Internal medicine
6 authors
From GB, US
- Ulrich Amon · corresponding
- Laura Baier
- Raul Yaguboglu
- Madeleine EnnisQueen's University Belfast
- Michael F. HolickBoston University; Boston Medical Center
- Julian Amon
Abstract
The pathogenetic role of vitamin D as well as its clinical correlation in inflammatory skin diseases is still uncertain. This study aimed to compare serum levels of 25(OH) vitamin D (calcidiol) in outpatients suffering from different skin diseases using the same laboratory method in one study. In routine serum samples of 1,532 patients from the previous 12 months we identified retrospectively 180 (mean age 49.4 years, 80 female, 100 male) and 205 (mean age 36.3 years, 116 female, 89 male) patients with psoriasis (PSO) and atopic dermatitis (AD), respectively. Clinical disease activity and quality of life was evaluated using Physicians Global Assessment Scores (PGA), Dermatology Life Quality Index (DLQI), and a Visual Analog Scale for pruritus in AD, respectively. The median 25(OH)D serum level of all patients (22.97 ng/mL, range 2.61-96.0, n = 1,461) was significantly lower in comparison to healthy controls (41.6 ng/mL, range 16.9-77.57, p p p = 0,007 vs. PSO). For PSO and AD there was no significant correlation between 25(OH)D levels and PGA scores and DLQI values, respectively, or the extent of pruritus in AD. 25(OH)D serum levels in inflammatory skin diseases might correlate more with the type of disease and the degree of inflammation than with clinical activity itself.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.